EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Retired actor Gene Hackman has just celebrated his 95th birthday, and many fans and industry professionals have taken to ...

Women aged 18 to 45 years with IBD were invited to complete a survey regarding knowledge, attitude, and beliefs about contraception.

Kennedy wants to create "wellness drug rehabilitation farms." But the U.S. tried it before, and it didn't work.

The Trump administration has made some concessions to the halt placed on distributions of global HIV treatments via the U.S.

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...

Montelukast does not appear to increase the risk for neuropsychiatric adverse events in children and adolescents, according to a study published in JAMA Pediatrics. Montelukast is a leukotriene ...

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...

Cidara will also participate in one-on-one investor meetings during this event. Investors interested in meeting with Cidara ...